Granules India consolidated Q3 FY26 PAT rises to Rs. 150.21 Cr
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
Berendsen brings over 15 years of financial leadership experience spanning professional services and international trade
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
GCCL aims to leverage the partnership to expand strategic relationships with global CROs
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
Subscribe To Our Newsletter & Stay Updated